This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yao-Borengasser, A. Articles by Kern, P. A. Search for Related Content PubMed PubMed Citation Articles by Yao-Borengasser, A. Articles by Kern, P. A. Related Collections Metabolism

Stearoyl-Coenzyme A Desaturase 1 Gene Expression Increases after Pioglitazone Treatment and Is Associated with Peroxisomal Proliferator-Activated Receptor- Responsiveness

The Central Arkansas Veterans Healthcare System and the Department of Medicine (A.Y.-B., N.Rass., V.V., A.M.B., N.Raso., R.U., B.P., G.R., P.A.K.), Division of Endocrinology, Department of Pediatrics (R.E.M.), and the Winthrop P. Rockefeller Cancer Institute (R.E.M.), University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205

Address all correspondence and requests for reprints to: Philip A. Kern, M.D., Research, 598/151, Central Arkansas Veterans Healthcare System, 4300 West 7th Street, Little Rock, Arkansas 72205. E-mail: kernphilipa{at}uams.edu.

Context and Objective: Stearoyl-coenzyme A desaturase (SCD1) is the rate-limiting enzyme that converts palmitoyl- and stearoyl-coenzyme A to palmitoleoyl- and oleoyl-cownzyme A, respectively. SCD-deficient mice are protected from obesity, and the ob/ob mouse has high levels of SCD. This study was designed to better characterize SCD1 gene and protein expression in humans with varying insulin sensitivity.

Design, Participants, and Setting: In a university hospital clinical research center setting, SCD1 gene expression was measured in sc adipose and vastus lateralis muscle of 86 nondiabetic subjects; 10 wk of pioglitazone (45 mg daily) and metformin (1000 mg twice daily) treatment were assessed in 36 impaired glucose-tolerant subjects. Adipocytes were treated with pioglitazone, and SCD1 expression was attenuated with small interfering RNA (siRNA) to examine other adipocyte genes.

Results: There was no significant relationship between adipose or muscle SCD1 mRNA and either body mass index or insulin sensitivity. After pioglitazone (but not metformin) treatment, there was a 2-fold increase in SCD1 mRNA and protein in adipose tissue. Pioglitazone also increased SCD1 in vitro. There were significant positive correlations between SCD1 and peroxisomal proliferator-activated receptor (PPAR) as well as other PPAR-responsive genes, including lipin-β, AGPAT2, RBP4, adiponectin receptors, CD68, and MCP1. When SCD1 expression was inhibited with a siRNA, lipin-β, AGPAT2, and the adiponectin R2 receptor expression were decreased, and adipocyte MCP-1 was increased.

Conclusions: SCD1 is closely linked to PPAR expression in humans, and is increased by PPAR agonists. The change in expression of some downstream PPAR targets after SCD1 knockdown suggests that PPAR up-regulation of SCD1 leads to increased lipogenesis and potentiation of adiponectin signaling.